SCHEMBL25754765

SCHEMBL25754765

CNC(=O)CNCCc1cscn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 4/20 0.34
LMNA P02545 2/20 0.34
PKM P14618 1/20 0.34
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
F10 P00742 1/20 0.32
PDE10A Q9Y233 1/20 0.32
MAP3K5 Q99683 1/20 0.32
GPR142 Q7Z601 1/20 0.32
GAA P10253 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SLC6A3 Q01959 1/20 0.31
NTRK1 P04629 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23118696 0.77 MAPK1 (0.47) MAPTMAPK1NPSR1KDM4CALDH1A1
SCHEMBL25754985 0.76 TBXAS1 (0.40) MAPK1NPSR1KDM4CPKM
SCHEMBL11323939 0.75 MAPT (0.32) MAPTNPC1RAB9AMAPK1NPSR1
SCHEMBL8813734 0.75 MAPT (0.39) MAPTNPC1RAB9AMAPK1NPSR1
SCHEMBL11323948 0.74 KDM4E (0.35) MAPTNPC1RAB9AALDH1A1KDM4E
SCHEMBL12011089 0.73 HRH3 (0.58) MAPTRAB9AMAPK1ALDH1A1LMNA
SCHEMBL25754767 0.73 NAMPT (0.33) ALDH1A1LMNAIKBKBCHUKGAA
SCHEMBL6679224 0.72 NPC1 (0.42) MAPTNPC1RAB9AMAPK1NPSR1
SCHEMBL25754983 0.71 GAA (0.33) MAPK1NPSR1KDM4CPKMGAA
SCHEMBL25754984 0.70 GAA (0.35) MAPK1NPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 MAPT 1198/4885NPC1 4242/4885RAB9A 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.